

## What Clinicians Want to Know: Addressing Current Questions and Controversies in the Care of Patients with Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the mechanism of action of nemvaleukin alfa?
  - a. Folate receptor alpha-directed antibody-drug conjugate
  - b. IL-2 variant**
  - c. Glucocorticoid receptor modulator
  - d. Anti-PD-1 monoclonal antibody
2. Which of the following any-grade adverse events is most commonly reported with raludotatug deruxtecan?
  - a. Headache
  - b. Nausea**
  - c. Peripheral neuropathy
  - d. Thrombocytopenia
3. A post hoc exploratory analysis of the Phase III KEYLYNK-001 trial suggested a survival benefit in the pembrolizumab/olaparib group vs chemotherapy in which of the following subgroups of patients with non-BRCA mutated, advanced ovarian cancer?
  - a. Patients with loss of heterozygosity (LOH)-high disease
  - b. Patients with LOH-low disease who received prior bevacizumab
  - c. Patients with LOH-low disease and no prior bevacizumab**
  - d. B and C only
4. In the Phase III MIRASOL study, mirvetuximab soravtansine demonstrated an improvement in which of the following metrics for patients with FR $\alpha$ -positive, high-grade serous platinum-resistance ovarian cancer versus investigator's choice of chemotherapy?
  - a. Objective response rate
  - b. Progression-free survival
  - c. Overall survival
  - d. All of the above**
  - e. A and B only
5. Which of the following antiemetics should be avoided by patients receiving a PARP inhibitor?
  - a. Olanzapine
  - b. Ondansetron
  - c. Dolasetron
  - d. Aprepitant**